Original article| Volume 124, ISSUE 2, P255-262, August 1994

Download started.


Soluble CD antigen (cytokine) expression in various hyperthyroid states and use in the assessment of propylthiouracil treatment

  • Edward Dennis Murphy
    Reprint requests: E. Dennis Murphy, MD, 530 Winnetka Ave., Winnetka, IL 60093.
    From the Department of Medicine, The Evanston Hospital Evanston, Illinois USA

    Northwestern University Medical School Chicago, Illinois USA
    Search for articles by this author
  • Pat Kallio
    From the Department of Medicine, The Evanston Hospital Evanston, Illinois USA

    Northwestern University Medical School Chicago, Illinois USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      The soluble CD antigens sCD8, sCD23, and sCD25 are increased in untreated Graves' hyperthyroidism. These levels remain elevated when euthyroidism is established in response to propylthiouracil (PTU) therapy but decrease to control values after PTU treatment is discontinued, when euthyroldlsm has been established and maintained. Neither sCD8 nor sCD23 are elevated in patients with euthyroid Graves' ophthalmopcrthy nor in the hyperthyroid phase of subacute thyroidltis. sCD25 is increased to an intermediate degree in these disorders. Soluble CD8 ≥ 450 U/ml is sensitive, specific, and predictive of PTU success as sole therapy or need for definitive therapy in untreated and PTU-treated Graves' hyperthyroidism, exceeding the predictive values of thyroid-stimulating hormone receptor antibody, thyroid peroxidase antibody, and T3 radioimmunoassay.


      IL-2R (interleukin-2R), PTU (propylthiouracil), RAI (radioactive iodine), RIA (radioimmunoassay), sCD (soluble cluster of differentiation), TPO (thyroid peroxidase), TSH (thyroid-stimulating hormone), TSHrAb (TSH receptor antibody)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lynch RG
        • Sandor M
        • Nunez R
        • et al.
        Lymphocyte Fc receptors: the immunobiology and pathology of CD23.
        Immunobiology. 1992; 185: 235-267
        • Fujimoto J
        • Levy S
        • Levy R
        Spontaneous release of the Leu 2(T8) molecule from human T cells.
        J Exp Med. 1983; 158: 752-766
        • Sarfati M
        • Rector E
        • Wong K
        • Rubio-Trujillo M
        • Schon AH
        • Delespesse G
        Possible role of human lymphocyte receptor for IgE (CD23) or its soluble fragments in the in vitro synthesis of human IgE.
        J Immunol. 1988; 141: 495-499
        • Rubin LA
        • Kurman CC
        • Fritz ME
        • et al.
        Soluble interleukin-2 receptors are shed by activated human lymphocytes in vitro.
        in: Fed Proc. 44. 1985: 946
        • Smith BR
        • McLachlan SM
        • Furmaniak J
        Autoantibodies to the thyrotropin receptor.
        Endocr Rev. 1988; 9: 106-121
        • Rubin LA
        • Nelson DL
        The soluble interleukin-2 receptor: biology, function and clinical application.
        Ann Intern Med. 1990; 113: 619-627
        • Balasz CZ
        • Farid NR
        Soluble interleukin-2 receptor in sera of patients with Graves' disease.
        J Autoimmun. 1991; 4: 681-688
        • Chow CC
        • Lai KN
        • Leung JCK
        • Chan JCN
        • Cockram CC
        Serum soluble interleukin-2 receptors in hyperthyroid Graves' disease and effect of carbimazole therapy.
        Clin Endocrinol. 1990; 33: 317-321
        • Wilson R
        • McKillop JH
        • Buchanan LM
        • Bradley H
        • Smith WE
        • Thomson JA
        The effect of carbimazole therapy on interleukin-2, interleukin-2 receptors and free radicals.
        Autoimmunity. 1990; 8: 3-7
        • Prummel MF
        • Wiersinga WM
        • VanDerGaag R
        • Mourits MP
        • Koornneef L
        Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.
        Clin Exp Immunol. 1992; 88: 405-409
        • Tomkinson BE
        • Brown MC
        • Ip SH
        • Carrabis S
        • Sullivan JL
        Soluble CD8 during T cell activation.
        J Immunol. 1989; 142: 2230-2236
        • Gordon J
        • Guy GR
        The molecules controlling B lymphocytes.
        Immunol Today. 1987; 8: 339-344
        • Pui CH
        • Ip SH
        • Dodge RK
        • et al.
        Serum levels of CD8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patients.
        Blood. 1988; 72: 1015-1021
        • Pui CH
        • Ip SH
        • Thompson E
        • et al.
        Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome.
        Blood. 1988; 73: 209-213
        • Genot E
        • Sarfati M
        • Sigaux F
        • et al.
        Effect of interferon-a on the expression and release of CD23 molecule in hairy cell leukemia.
        Blood. 1989; 74: 2455-2463
        • Fujimoto J
        • Stewart ST
        • Levy R
        Immunochemical analysis of the released Leu-2 (T8) molecule.
        J Exp Med. 1984; 160: 116
        • Agostini C
        • Semenzato G
        • Vinante F
        • et al.
        Increased levels of soluble CD8 molecules in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders.
        Clin Immunol Immunopathol. 1989; 50: 146
        • Reddy MM
        • Lange M
        • Greico MH
        Elevated soluble CD8 levels in sera of human immunodeficiency virus-infected populations.
        J Clin Microbiol. 1989; 27: 257-260
        • Lai RB
        • Ramzy RM
        • Gad AA
        Elevated levels of soluble CD8 molecules in patients with lymphatic filariasis.
        Immunol Lett. 1990; 26: 85
        • Ho AD
        • Grossman M
        • Trumper L
        • et al.
        Clinical implications of increased plasma levels of CD8 in patients with hairy cell leukemia.
        Blood. 1990; 75: 1119-1124
        • Symons JA
        • Wood NC
        • Di Giovine FS
        • Duff GW
        Soluble CD8 in patients with rheumatic diseases.
        Clin Exp Immunol. 1990; 80: 354-359
        • Cairns J
        • Flores-Romo L
        • Millsum MJ
        • et al.
        Soluble CD23 is released by B lymphocytes cycling in response to interleukin-4 and anti-Bp50 (CDW 40).
        Eur J Immunol. 1988; 18: 349-353
        • Sarfati M
        • Bron D
        • Lagneaux L
        • Fonteyn C
        • Frost H
        • Delespesse G
        Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia.
        Blood. 1988; 71: 94-98
        • Bansal A
        • Roberts T
        • Hay EM
        • Kay R
        • Pumphrey RSH
        • Wilson PB
        Soluble CD23 levels are elevated in the serum of patients with primary Sjogren's Syndrome and systemic lupus erythematosus.
        Clin Exp Immunol. 1992; 89: 452-455
        • Small T
        • Keever C
        • Weiner-Fedus S
        • Heller G
        • O'Reilly R
        • Flomenberg N
        B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny.
        Blood. 1990; 76: 1647-1656
        • Komp DM
        • Shapiro E
        • McNamara J
        Soluble interleukin-2 receptor in childhood non-Hodgkin's Syndrome.
        Blood. 1988; 31: 1172-1173
        • Wagner DK
        • Kiwanuka J
        • Edwards BK
        • Rubin LA
        • Nelson DL
        • Magrath IT
        Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas correlation with survival.
        J Clin Oncol. 1987; 5: 1262-1267
        • Steis RG
        • Marcon L
        • Clark J
        • et al.
        Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia.
        Blood. 1987; 71: 1304-1309
        • Chilosi M
        • Semenzato R
        • Cetto G
        • et al.
        Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of alpha-interferon therapy on clinical parameters and on natural killer in vitro activity.
        Blood. 1987; 70: 1530-1535
        • Prince HE
        • Kleinman SH
        • Maino VC
        • Jackson AL
        In vitro activation of T lymphocytes from human immunodeficiency virus (HIV)-seropositive blood donors. I. Soluble interleukin-2 receptor (IL-2R) production parallels cellular IL-2R expression and DNA synthesis.
        J Clin Immunol. 1988; 8: 114-120
        • Reddy MM
        • Grieco MH
        Elevated interleukin-2 receptor levels in serum of human immunodeficiency virus infected populations.
        Aids Res Hum Retroviruses. 1988; 4: 115-120
        • Mahida YR
        • Gallagher A
        • Kurlak L
        • Hawkey CJ
        Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease.
        Clin Exp Immunol. 1990; 82: 75-80
        • Colvin RB
        • Fuller TC
        • MacKleen L
        • Rung S
        • Ip SH
        • Cosimi AB
        Plasma interleukin-2 receptor levels in renal allograft recipients.
        Clin Immunol Immunopathol. 1987; 43: 273-276
        • Rubini LA
        The soluble interleukin-2 receptor in rheumatic disease.
        Arthritis Rheum. 1990; 33: 1145-1148
        • Nelson DL
        • Rubin LA
        • Kurman CC
        • Fritz ME
        • Boutin B
        Soluble interleukin-2 receptors: analysis in normal individuals and in certain disease states.
        in: Fed Proc. 45. 1986: 377
        • Young ET
        • Steel NR
        • Taylor JJ
        • Stephenson AM
        • et al.
        Prediction of remission after antithyroid drug treatment in Graves' disease.
        QJ Med. 1988; 250: 175-189
        • Hufner M
        • Wermann M
        • GruBendorf M
        • Heilig B
        Is soluble CD25 antigen (interleukin-2 receptor) a useful parameter for differential diagnosis of thyrotoxicosis?.
        Clin Invest. 1992; 70: 122-124
        • Wilson R
        • McKillop JH
        • Pearson C
        • Burnett AK
        • Thomson JA
        Differential immunosuppressive action of carbimazole and propylthiouracil.
        Clin Exp Immunol. 1988; 73: 312-315
        • Wilson R
        • McKillop JH
        • Henderson N
        • Pearson DW
        • Thomson JA
        The ability of the serum thyrotropin antibody (TRAb) index and HLA status to predict long term remission of thyrotoxicosis following medical therapy for Graves' disease.
        Clin Endocrinol. 1986; 25: 151
        • Maccia E
        • Concetti R
        • Borgoni F
        • Fenzi GF
        • Pinchlia A
        Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: Their incidence, significance and clinical usefulness.
        Autoimmunity. 1989; 3: 103-112
        • Czarnocka B
        • Ruf J
        • Ferrand M
        • Carayon P
        • Lissitzky S
        Purification of the human thyroid peroxidase and its identification as the microsomal antigen involved in autoimmune thyroid disease.
        FEBS Lett. 1985; 190: 147-152
        • Takaichi Y
        • Tamai H
        • Honda K
        • Nagai K
        • et al.
        The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves' disease treated with antithyroidal drugs.
        J Clin Endocrinol Metab. 1989; 68: 1093-1100
        • Solomon B
        • Glinoer D
        • LaGasse R
        • Wartofsky L
        Current trends in the management of Graves' disease.
        J Clin Exp Med. 1990; 70: 1518-1524
        • Koukkou E
        • Panayiotidis P
        • Alevizou-Terzaki V
        • Thalassinos N
        High levels of serum interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.
        J Clin Endocrinol Metab. 1991; 73: 771-776